ClinicalTrials.gg
Active, not recruitingNCT05985915NEPTUNUS-ExtUpdated Oct 15, 2026

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

A Phase 3 interventional study of Ianalumab (VAY736) and Placebo in Sjogrens Syndrome, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 198 sites in 35 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Oct 15, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
2nd of 14
612 · median 240
Started
2023
the only one that year
Phase 3
4 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 3, and was the 12th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 [NCT05350072] or CVAY736A2302 [NCT05349214]).

Read the detailed description

This is a multicenter, randomized, double-blind, followed by an open-label, phase 3 study to assess the long-term safety and tolerability of of 300 mg ianalumab s.c. injection in participants with Sjögren's syndrome who have taken part in and completed one of two NEPTUNUS core studies, NEPTUNUS-1 (CVAY736A2301) or NEPTUNUS-2 (CVAY736A2302).

There will be no screening period in this trial. From Week 48 of the NEPTUNUS core study, participants will be given the opportunity to consent to this extension study. Eligible participants will enter the double blind treatment period and receive ianalumab 300 mg either monthly or every three months, consistent with their prior treatment assignment. Participants previously randomized to placebo in the core studies will be randomized 1:1 to receive ianalumab 300 mg monthly or every three months, starting at Week 60. Participants assigned to every three month dosing will receive monthly placebo injections between active doses to maintain blinding.

The study treatment is ianalumab 300 mg in a 2 mL pre-filled syringe (PFS) in needle safety device for injection or ianalumab via 2 mL autoinjector (AI). An AI is a device constituent of a single integral, or single entity, drug-device combination product, with drug primary mode of action. Participants already enrolled into the study (before AI approval and implementation) will continue receiving the treatment via PFS and will not be switched to AI.

All participants, including those previously on ianalumab 300 mg every three months or monthly in the double-blind treatment period will switch to open-label treatment and receive ianalumab 300 mg monthly. The treatment duration including both double-blind and open-label treatment periods will be 6 years. After the treatment period, all participants will enter a follow-up period to be monitored for at least 20 weeks and then a conditional (if B-cell recovery criteria have not been met) follow-up period. The total post treatment follow-up period is up to 2 years. The total duration of this extension study will be up to 8 years.

03

Conditions studied

  • Sjogrens Syndrome

Browse trials for

Keywords

  • Sjogrens Syndrome
  • ianalumab
  • VAY736
  • NEPTUNUS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to participation in the extension study.
  2. Participants must have participated in either one of the two NEPTUNUS core studies, CVAY736A2301 or CVAY736A2302, and must have completed the entire treatment up to Week 48 without treatment discontinuation in core NEPTUNUS studies.
  3. In the judgement of the Investigator, participants must be expected to clinically benefit from continued ianalumab therapy.

Exclusion criteria

Exclusion Criteria:

  1. Use of therapies excluded by the NEPTUNUS-1 and NEPTUNUS-2 study protocols (see NEPTUNUS studies protocols exclusion criteria in Section 5.2 for details).
  2. Plans for administration of during the study period.
  3. Pregnant or nursing (breastfeeding) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.
  4. Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, from menarche until becoming , unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., hormonal profile confirming menopause and/or age-appropriate history of vasomotor symptoms).

    WOCBP are excluded unless they are using highly effective methods of (failure rate \< 1% per year) while taking study treatment during dosing and for 6 months after stopping of drug. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post- ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Bilateral tubal occlusion or bilateral tubal ligation (at least six weeks before taking study treatment).
    • Sterilization (vasectomy) of male partner (s) of the female participant at least 6 months prior to screening provided partner(s) has(have) received medical confirmation of surgical process.
    • Use of hormonal contraception methods:
    • Combined (estrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal.
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable.
    • Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

    Contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.

    If local regulations are more stringent than the contraception methods listed above, local regulations apply and will be described in the form (ICF).

  5. United States (and other countries, if male contraception is locally required): Sexually active males, unless they agree to use barrier protection during intercourse with a woman of child-bearing potential, while taking study treatment. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended that female partners of male study participants use a second method of birth control. Although ianalumab is not teratogenic and/or genotoxic, and not transferred to semen, male contraception is required, as requested by FDA.

Globally, for all sexually active males, contraception should be used in accordance with the locally approved prescribing information of concomitant medications administered.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
612 participants (actual)

Study arms

  • Experimental
    Ianalumab Monthly

    Ianalumab 300 mg s.c. monthly during initial double-blind treatment period. Open-label treatment and receive ianalumab 300 mg monthly.

    Drug: Ianalumab (VAY736)

  • Experimental
    Ianalumab 3 Monthly

    Ianalumab 300 mg s.c. every three months and placebo once monthly between doses during initial double-blind treatment period. Open-label treatment and receive ianalumab 300 mg monthly.

    Drug: Ianalumab (VAY736) · Other: Placebo

Interventions

  • Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use

    Also known as: VAY736

  • OtherPlacebo

    Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent AEs (TEAEs)/SAEs

    Assessment of safety and tolerability of ianalumab (VAY736) in patients with active Sjogrens syndrome

    Time frame: Week 52 to Week 464

Secondary outcomes

  1. Percentage of participants achieving ≥ 5 points reduction from baseline in ESSDAI

    EULAR Sjogren's syndrome disease activity index (ESSDAI) is a validated clinical disease outcome measure for Sjogrens that will be used in the study The instrument contains 12 organ-specific domains contributing to assessment of disease activity. For each domain, features of disease activity are scored by a clinician in 3 or 4 (Level 0=No disease activity to Level 3= high disease activity) levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score. The maximum possible score is 123.To calculate ESSDAI, all 12 organ domains must be individually assessed by a trained assessor (study Investigator) at every scheduled timepoint. This is to evaluate the long-term efficacy of VAY736 300 mg administered monthly or every 3 months.

    Time frame: Over time up to Week 360

  2. Percentage of participants achieving ≥2.3 points reduction from baseline in ESSPRI among participants with baseline ESSPRI ≥3 score over time

    The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) questionnaire consists of three items to be given an activity level score between 0-10: pain (joint and/or muscle pain), fatigue and dryness (0 = no symptom at all and 10 = worst symptom imaginable ESSPRI is an established disease outcome measure for Sjogrens. It consists of three domains of dryness, pain and fatigue. The participant will assess severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as a mean of scores from the three scales: (dryness + pain + fatigue) /3.

    Time frame: Over time up to Week 360

  3. Percentage of participants achieving ≥2.0 points reduction from baseline in SSSD among participants with baseline SSSD ≥3

    The Sjogrens Syndrome Symptom Diary (SSSD) questionnaire consists of five (six for females) questions about symptoms of Sjögren's syndrome, each question given a score of 0-10 (0=no symptoms, 10=worst possible symptoms) where patient choose the one response that best describes how severe the symptom was at its worst in the PAST 24 HOURS. It includes six symptom items (eye dryness, mouth dryness, skin dryness, physical fatigue, muscle and/or joint pain, genital dryness), and applies a recall period of 24 hrs. The aim of the SSSD is to establish patient reported endpoints for the treatment of Sjogrens syndrome. Participants will complete the diary daily for 7 days prior to the scheduled dosing.

    Time frame: Over time up to Week 360

  4. Pre-dose Ianalumab serum concentrations

    To show comparability of ianalumab Ctrough between 2x 1 mL PFS (from the NEPTUNUS core studies) and 1x 2 mL PFS for participants on continuous monthly treatment.

    Time frame: pre-dose at Week 48 (from core study) and Week 64

  5. On-treatment Ianalumab serum concentrations

    To further assess the pharmacokinetics of ianalumab.

    Time frame: During treatment (from Week 52 to Week 204) and follow-up (From Week 208 to Week 304)

  6. B-cell count measurement

    To assess impact of long-term treatment on B-cell depletion.

    Time frame: Week 52 to Week 304

07

Study locations

198 sites
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • Advanced Medical Research
    La Palma, California 90623, United States
  • Medvin Clinical Research
    Van Nuys, California 91405, United States
  • Bay Area Arthritis And Osteoporosis
    Brandon, Florida 33511, United States
  • GNP Research
    Cooper City, Florida 33024, United States
  • Sarasota Arthritis Res Ctr
    Sarasota, Florida 34239, United States
  • West Broward Rheumatology Associates Inc
    Tamarac, Florida 33321, United States
  • Augusta University Georgia
    Augusta, Georgia 30912, United States
  • North GA Rheumatology Group PC
    Suwanee, Georgia 30024, United States
  • Clin Invest Specialists Inc
    Orland Park, Illinois 60467, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Ochsner Health System
    Baton Rouge, Louisiana 70809, United States
  • The John Hopkins Jerome L Greene Sjogren
    Baltimore, Maryland 21224, United States
  • Tufts School of Dental Medicine
    Boston, Massachusetts 02111, United States
  • Arthritis Osteoporosis Assoc of NM
    Las Cruces, New Mexico 88011, United States
  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • St Lawrence Health System
    Potsdam, New York 13676, United States
  • Arthritis and Osteoporosis
    Charlotte, North Carolina 28202, United States
  • On Site Clinical Solutions Llc
    Charlotte, North Carolina 28202, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • STAT Research Inc
    Dayton, Ohio 45402, United States
  • RAO Research LLC
    Oklahoma City, Oklahoma 73116, United States
  • Altoona Center for Clin Res
    Duncansville, Pennsylvania 16635, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Shelby Research LLC
    Memphis, Tennessee 38119, United States
  • Precision Comprehensive Research
    Colleyville, Texas 76034, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Houston Rheumatology and Arthrit
    Katy, Texas 77494, United States
  • First Outpatient Research Unit
    San Antonio, Texas 78229, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • Arthritis Northwest PLLC
    Spokane, Washington 99216, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1405BCH, Argentina
  • Novartis Investigative Site
    Quilmes, Buenos Aires 1878, Argentina
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province T4000DPK, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1055AAF, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1437FFC, Argentina
  • Novartis Investigative Site
    CABA, C1428DZF, Argentina
  • Novartis Investigative Site
    Maroochydore, Queensland 4558, Australia
  • Novartis Investigative Site
    Woodville South, South Australia 5011, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Vitória, Espírito Santo 29055-450, Brazil
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40150-150, Brazil
  • Novartis Investigative Site
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Novartis Investigative Site
    Ribeirão Preto, São Paulo 14048-900, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04266-010, Brazil
  • Novartis Investigative Site
    São Paulo, 01409-902, Brazil
  • Novartis Investigative Site
    Burgas, Bulgaria 8000, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1L7, Canada
  • Novartis Investigative Site
    Sydney, Nova Scotia B1P 1P3, Canada
  • Novartis Investigative Site
    Rimouski, Quebec G5L 5T1, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1G 2E8, Canada
  • Novartis Investigative Site
    Trois-Rivières, Quebec G9A 3Y2, Canada
  • Novartis Investigative Site
    Concepción, Biobio 4070280, Chile
  • Novartis Investigative Site
    Valdivia, Los Ríos Region 5110683, Chile
  • Novartis Investigative Site
    Santiago, RM 7500588, Chile
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 7500571, Chile
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 7500710, Chile
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Chongqing, Chongqing Municipality 400010, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510630, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518020, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014010, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Pingxiang, Jiangxi 337000, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
  • Novartis Investigative Site
    Linyi, Shandong 276000, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030000, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Yinchuan, The Ningxia Hui Autonomous Reg 750000, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Shanghai, 200011, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Xinxiang, 453099, China
  • Novartis Investigative Site
    Medellín, Antioquia 050001, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Bogota, Cundinamarca 110221, Colombia
  • Novartis Investigative Site
    Bucaramanga, Santander Department 680003, Colombia
  • Novartis Investigative Site
    Brno, 638 00, Czechia
  • Novartis Investigative Site
    Uherské Hradiště, 686 01, Czechia
  • Novartis Investigative Site
    Angers, France 49933, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Saint-Priest-en-Jarez, 42270, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany

Showing the first 100 of 198 sites across 35 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Apr 2033, 113 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 14, 2023
StartActual
Oct 27, 2023
Primary completionEst.
Apr 22, 2033
CompletionEst.
Apr 22, 2033
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 Mexico, 1 Turkey (Türkiye))
  • Novartis Investigative Site · Mexico City, Mexico
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 2 removed
  • Novartis Investigative Site · México, Mexico
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Mexico, 1 Turkey (Türkiye))
    • Novartis Investigative Site · Mexico City, Mexico
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 2 removed
    • Novartis Investigative Site · México, Mexico
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05985915
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Oct 27, 2023
Primary completion
Apr 22, 2033 (estimated)
Completion
Apr 22, 2033 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion